{"id":20146,"date":"2023-03-31T23:23:00","date_gmt":"2023-03-31T15:23:00","guid":{"rendered":"https:\/\/flcube.com\/?p=20146"},"modified":"2024-12-28T23:27:44","modified_gmt":"2024-12-28T15:27:44","slug":"apollomics-inc-completes-merger-with-maxpro-capital-lists-on-nasdaq-as-aplm","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20146","title":{"rendered":"Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as &#8216;APLM&#8217;"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Sino-US biotech firm Apollomics Inc. has announced the successful completion of a merger with the special purpose acquisition company (SPAC) Maxpro Capital Acquisition Corp., This strategic move allows Apollomics&#8217; A shares and warrants to be traded on the NASDAQ under the ticker symbols \u201cAPLM\u201d and \u201cAPLMW\u201d respectively. The merger, which was approved by Maxpro&#8217;s shareholders on March 20, 2023, is projected to inject USD 23.65 million into Apollomics, funds that are designated for research and development efforts. Dr. Yu Guoliang will continue in his role as CEO and director of the board for Apollomics.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Apollomics&#8217; Global Presence and Support<\/strong><br>Officially headquartered in Foster City, California, Apollomics Inc. maintains a robust presence in China with operations in Shanghai and Hangzhou. The company enjoys the support of a diverse group of Chinese investors, including Ping An Capital, China Renaissance, and CMB International, among others. Apollomics is actively developing a pipeline of nine assets, which encompasses both small-molecule drugs and biologics.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Pipeline Highlights and Clinical Progress<\/strong><br>The company&#8217;s pipeline is spearheaded by vebreltinib, a c-Met inhibitor that is in pivotal Phase II studies for non-small cell lung cancer (NSCLC), with expectations to support a future US New Drug Application (NDA) filing. Additionally, uproleselan, an E-selectin antagonist, is in Phase III trials in China for the treatment of relapsed or refractory acute myeloid leukemia (AML). This molecule has previously been granted breakthrough therapy designations (BTDs) in both the US and China, highlighting its potential impact on patient care.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sino-US biotech firm Apollomics Inc. has announced the successful completion of a merger with the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[1927,30,20,72],"class_list":["post-20146","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-apollomics","tag-biotech","tag-finance","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as &#039;APLM&#039; - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino-US biotech firm Apollomics Inc. has announced the successful completion of a merger with the special purpose acquisition company (SPAC) Maxpro Capital Acquisition Corp., This strategic move allows Apollomics&#039; A shares and warrants to be traded on the NASDAQ under the ticker symbols \u201cAPLM\u201d and \u201cAPLMW\u201d respectively. The merger, which was approved by Maxpro&#039;s shareholders on March 20, 2023, is projected to inject USD 23.65 million into Apollomics, funds that are designated for research and development efforts. Dr. Yu Guoliang will continue in his role as CEO and director of the board for Apollomics.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20146\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as &#039;APLM&#039;\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20146\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-31T15:23:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-28T15:27:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20146#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20146\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as &#8216;APLM&#8217;\",\"datePublished\":\"2023-03-31T15:23:00+00:00\",\"dateModified\":\"2024-12-28T15:27:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20146\"},\"wordCount\":259,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Apollomics\",\"Biotech\",\"Finance\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20146#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20146\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20146\",\"name\":\"Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as 'APLM' - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-03-31T15:23:00+00:00\",\"dateModified\":\"2024-12-28T15:27:44+00:00\",\"description\":\"Sino-US biotech firm Apollomics Inc. has announced the successful completion of a merger with the special purpose acquisition company (SPAC) Maxpro Capital Acquisition Corp., This strategic move allows Apollomics' A shares and warrants to be traded on the NASDAQ under the ticker symbols \u201cAPLM\u201d and \u201cAPLMW\u201d respectively. The merger, which was approved by Maxpro's shareholders on March 20, 2023, is projected to inject USD 23.65 million into Apollomics, funds that are designated for research and development efforts. Dr. Yu Guoliang will continue in his role as CEO and director of the board for Apollomics.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20146#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20146\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20146#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as &#8216;APLM&#8217;\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as 'APLM' - Insight, China&#039;s Pharmaceutical Industry","description":"Sino-US biotech firm Apollomics Inc. has announced the successful completion of a merger with the special purpose acquisition company (SPAC) Maxpro Capital Acquisition Corp., This strategic move allows Apollomics' A shares and warrants to be traded on the NASDAQ under the ticker symbols \u201cAPLM\u201d and \u201cAPLMW\u201d respectively. The merger, which was approved by Maxpro's shareholders on March 20, 2023, is projected to inject USD 23.65 million into Apollomics, funds that are designated for research and development efforts. Dr. Yu Guoliang will continue in his role as CEO and director of the board for Apollomics.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20146","og_locale":"en_US","og_type":"article","og_title":"Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as 'APLM'","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=20146","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-03-31T15:23:00+00:00","article_modified_time":"2024-12-28T15:27:44+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20146#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20146"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as &#8216;APLM&#8217;","datePublished":"2023-03-31T15:23:00+00:00","dateModified":"2024-12-28T15:27:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20146"},"wordCount":259,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Apollomics","Biotech","Finance","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20146#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20146","url":"https:\/\/flcube.com\/?p=20146","name":"Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as 'APLM' - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-03-31T15:23:00+00:00","dateModified":"2024-12-28T15:27:44+00:00","description":"Sino-US biotech firm Apollomics Inc. has announced the successful completion of a merger with the special purpose acquisition company (SPAC) Maxpro Capital Acquisition Corp., This strategic move allows Apollomics' A shares and warrants to be traded on the NASDAQ under the ticker symbols \u201cAPLM\u201d and \u201cAPLMW\u201d respectively. The merger, which was approved by Maxpro's shareholders on March 20, 2023, is projected to inject USD 23.65 million into Apollomics, funds that are designated for research and development efforts. Dr. Yu Guoliang will continue in his role as CEO and director of the board for Apollomics.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20146#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20146"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20146#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as &#8216;APLM&#8217;"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20146"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20146\/revisions"}],"predecessor-version":[{"id":20148,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20146\/revisions\/20148"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20146"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20146"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}